Glucagon-like peptide-1 receptor agonists (GLP-1RA) are increasingly utilized for obesity treatment due to their significant metabolic benefits, including weight loss and improved glycemic control. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.